learn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
Search
forLearn
5 / 801 resultslearn HYDROXYPROPYLGLUCONAMIDE
learn copper bisglycinate
learn Gluconolactone
learn mometasone furoate
Research
5 / 1000+ results
research Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome
Metformin improved insulin resistance and BMI in overweight Taiwanese women with PCOS, and a 2-hour insulin test may be a good screening tool.
research Hydrogel-Forming Microneedles for Transdermal Drug Delivery
Hydrogel-forming microneedles are a safe and effective method for delivering drugs through the skin.
research Use of metformin in pediatric age
Metformin helps manage diabetes, PCOS, and weight in kids but needs more research for long-term safety.
research Specific interpretation of hair concentrations in 2 fatal metformin intoxication cases
Hair analysis showed very high metformin levels in two fatal overdose cases, suggesting it's useful in forensics but sweat may affect results.
research Role of Metformin in Acanthosis Nigricans
Metformin may improve acanthosis nigricans by reducing insulin resistance.
Community Join
5 / 201 resultscommunity PP405: The Ultimate Hair Loss Drug for Complete Hair Growth
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
community 30 new hair per cm by extended release minoxidil
Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.